Prourokinase mutant that induces highly effective clot lysis without interfering with hemostasis

Circulation Research

Volumn 90, Issue 7, 2002, Pages 757-763

  Liu, Jian Ning ^a,b,d   Liu, Jian Xia ^b,c   Liu, Bei Fang ^b   Sun, Ziyong ^a,b   Zuo, Jian Ling ^c   Zhang, Pei Xiang ^b   Zhang, Jing ^b   Chen, Yu Hong ^b   Gurewich, Victor ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b NANJING UNIVERSITY   (China)

^c Department of Radiation Medicine   (China)

^d Deaconess Medical Center   (United States)

Author keywords

Activators; Animals; Bleeding; Fibrinolysis; Plasminogen

Indexed keywords

HEXAHYDRO 3,9 DIMETHYLINDENO[2,1 C]PYRIDINE; HISTIDINE; LYSINE; PLASMINOGEN ACTIVATOR; PROUROKINASE; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLEEDING TIME; BLOOD CLOT LYSIS; CONTROLLED STUDY; DOG; DRUG ACTIVITY; DRUG INFUSION; FEMALE; HEMOSTASIS; MALE; MUTANT; NONHUMAN; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; RHESUS MONKEY;

AMINO ACID SUBSTITUTION; ANIMALS; BLEEDING TIME; BLOOD COAGULATION; DISEASE MODELS, ANIMAL; DOGS; DRUG EVALUATION, PRECLINICAL; DRUG STABILITY; ENZYME ACTIVATION; FEMORAL VEIN; FIBRIN; FIBRINOLYSIS; HEMORRHAGE; HEMOSTASIS; HUMANS; MACACA MULATTA; MALE; MUTAGENESIS, SITE-DIRECTED; PLASMA; PLASMINOGEN; RECOMBINANT PROTEINS; THROMBOLYTIC THERAPY; THROMBOSIS; TISSUE PLASMINOGEN ACTIVATOR; URINARY PLASMINOGEN ACTIVATOR;

EID: 0037134414     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.RES.0000014825.71092.BD     Document Type: Article

References (32)

1. Effective and fibrin-specific clot lysis by a zymogen precursor form of urokinase (pro-urokinase): A study in vitro and in two animal species
2. Prourokinase: A study of its stability in plasma and a mechanism for its selective fibrinolytic effect
3. Characterization of the intrinsic fibrinolytic properties of pro-urokinase through a study of plasmin resistant mutant forms produced by site specific mutagenesis of lysine 158
4. 2-antiplasmin in fibrin-specific clot lysis with single-chain urokinase-type plasminogen activator in human plasma
5. The activation of plasminogen by single-chain urokinase or by two-chain urokinase: A demonstration that single chain urokinase has a low catalytic activity (pro-urokinase)
6. Randomized double-blind trial of recombinant pro-urokinase against streptokinase in acute myocardial infarction: PRIMI Trial Study Group
7. A site-directed mutagenesis of pro-urokinase which substantially reduces its intrinsic activity
8. Identification of a flexible loop (297-313) of urokinase-type plasminogen activator, which helps determine its catalytic activity
9. Analysis of the forces which stabilize the active conformation of urokinase-type plasminogen activator
10. Physiological consequences of loss of plasminogen activator gene function in mice
11. Fibrin deposition in tissue from endotoxin-treated mice correlates with decreases in the expression of urokinase-type but not tissue-type plasminogen activator
12. Factors contributing to increased vascular fibrinolytic activity in mongrel dogs
13. The tissue plasminogen activator and urokinase receptor in vivo during natural resolution of venous thrombus
14. A comparative study of the promotion of tissue plasminogen activator and pro-urokinase-induced plasminogen activation by fragments D and E-2 of fibrin
15. Identification and primary sequence of an unspliced human urokinase poly(A)+RNA
16. Efficient renaturation and fibrinolytic properties of prourokinase and a deletion mutant expressed in Escherichia coli as inclusion bodies
17. Purification and characterization of recombinant single-chain urokinase in Escherichia coli
18. Inactivation of the intrinsic activity of pro-urokinase in diisopropylfluorophosphate is reversible
19. The kinetics of plasminogen activation by thrombin-cleaved pro-urokinase and promotion of its activity by fibrin fragment E-2 and by tissue plasminogen activator
20. Fragment E-2 from fibrin substantially enhances pro-urokinase-induced glu-plasminogen activation: A kinetic study using a plasmin-resistant mutant pro-urokinase (Ala-158-rpro-UK)
21. Bovine plasminogen activator inhibitor 1: Specificity determinations and comparison of the active, latent, and guanidine-activated forms
22. Fibrinogen assay
23. Coronary thrombolysis in dogs with intravenously administered human pro-urokinase
24. Coronary thrombolysis with intravenously administered human tissue-type plasminogen activator produced by recombinant DNA technology
25. The complementary modes of action of tissue plasminogen activator (t-PA) and pro-urokinase (pro-UK) by which their synergistic effect on clot lysis may be explained
26. "Plasminogen steal" and clot lysis
27. A double-blind multicenter comparison of the efficacy and safety of saruplase and urokinase in the treatment of acute myocardial infarction: Report of the SUTAMI Study Group
28. Hemostatic changes after thrombolytic therapy with saruplase (unglycosylated single-chain urokinase-type plasminogen activator) and urokinase (two-chain urokinase-type plasminogen activator)
29. A transitional state of pro-urokinase which has a higher catalytic efficiency against Glu-plasminogen than urokinase
30. Comparison of the bleeding potential of vampire bat salivary plasminogen activator versus tissue plasminogen activator in an experimental rabbit model
31. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction
32. Tissue plasminogen activator and urokinase mediate the binding of Glu-plasminogen to plasma fibrin I: Evidence for new binding sites in plasmin-degraded fibrin I